Humira and Bronchiectasis - a phase IV clinical study of FDA data

Summary:

Bronchiectasis is reported as a side effect among people who take Humira (adalimumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Methotrexate, and have Ulcerative colitis.

The phase IV clinical study analyzes which people have Bronchiectasis when taking Humira. It is created by eHealthMe based on reports of 758,421 people who have side effects when taking Humira from the FDA, and is updated regularly.

What is Humira?

Humira has active ingredients of adalimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 761,396 Humira users. Check the latest studies of Humira.

What is Bronchiectasis?

Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection) is found to be associated with 781 drugs and 863 conditions by eHealthMe. Check the latest studies of Bronchiectasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

758,421 people reported to have side effects when taking Humira.
Among them, 592 people (0.08%) have Bronchiectasis.

Among these 592 people:

* Approximation only. Some reports may have incomplete information.

Do you take Humira and have Bronchiectasis?

- Check whether Bronchiectasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Humira:

Humira (761,396 reports)

Bronchiectasis treatments and more:

Bronchiectasis (12,460 reports)

How severe was Bronchiectasis and when was it recovered:

Bronchiectasis in Humira

Expand to all the drugs that have ingredients of adalimumab:

Bronchiectasis and drugs with ingredients of adalimumab (640 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Humira:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bronchiectasis:

Bronchiectasis (781 drugs)

Browse all the conditions that are associated with Bronchiectasis:

Bronchiectasis (863 conditions)

Related publications that referenced our studies

Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, Lee SM, Yoon HI, Yim JJ, Yoo CG, Chung HS, "Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis", The International Journal of Tuberculosis and Lung Disease, 2014 Mar .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, Lee SM, Yoon HI, Yim JJ, Yoo CG, Chung HS, "Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis", The International Journal of Tuberculosis and Lung Disease, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on adalimumab (the active ingredients of Humira) and Humira (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.